NEW YORK (GenomeWeb News) – GenVault has closed a $13 million round of financing with venture capital investors, the Carlsbad, Calif.-based firm said today.
GenVault said that it would use the funds to accelerate commercialization of its technologies for room temperature biosample preservation, storage and distribution for biobanking, translational medicine, and applied testing applications.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.